Oncopeptides AB (Oncopeptides AB) Days Sales Outstanding : 515.83 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB Days Sales Outstanding?

Oncopeptides AB's average Accounts Receivable for the three months ended in Mar. 2024 was $2.75 Mil. Oncopeptides AB's Revenue for the three months ended in Mar. 2024 was $0.49 Mil. Hence, Oncopeptides AB's Days Sales Outstanding for the three months ended in Mar. 2024 was 515.83.

The historical rank and industry rank for Oncopeptides AB's Days Sales Outstanding or its related term are showing as below:

ONPPF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.86 Med: 36.63 Max: 344.15
Current: 344.15

During the past 10 years, Oncopeptides AB's highest Days Sales Outstanding was 344.15. The lowest was 14.86. And the median was 36.63.

ONPPF's Days Sales Outstanding is ranked worse than
86.82% of 888 companies
in the Biotechnology industry
Industry Median: 72.34 vs ONPPF: 344.15

Oncopeptides AB's Days Sales Outstanding declined from Mar. 2023 (1,734.18) to Mar. 2024 (515.83).

Oncopeptides AB Days Sales Outstanding Historical Data

The historical data trend for Oncopeptides AB's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Days Sales Outstanding Chart

Oncopeptides AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

36.63

310.82

14.83

Oncopeptides AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															1,734.18	149.82	1,410.23	361.67	515.83

Competitive Comparison of Oncopeptides AB's Days Sales Outstanding

For the Biotechnology subindustry, Oncopeptides AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Days Sales Outstanding falls into.

Oncopeptides AB Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Oncopeptides AB's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.065	+	0.214)	/	2 )	/	3.434	*	365
=	0.1395					/	3.434	*	365
=	14.83

Oncopeptides AB's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (0.214	+	5.292)	/	2 )	/	0.487	*	365 / 4
=	2.753					/	0.487	*	365 / 4
=	515.83

Oncopeptides AB (OTCPK:ONPPF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Oncopeptides AB Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB (Oncopeptides AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OTCPK:ONPPF) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden 0RN4:UK OND:Germany OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.